鈴木　則宏 (スズキ　ノリヒロ)

Suzuki, Norihiro

写真a

所属（所属キャンパス）

医学部 （三田）

職名

名誉教授

外部リンク
このページの先頭へ▲

経歴 【 表示 ／ 非表示 】

  • 1993年04月
    -
    1998年05月

    水戸赤十字病院第一内科部長　兼　神経内科部長

  • 1997年04月
    -
    1998年05月

    水戸赤十字病院副院長

  • 1998年06月
    -
    2002年03月

    北里大学医学部内科学Ⅲ　専任講師

  • 1999年04月
    -
    2003年03月

    北里大学医学部　内科学Ⅲ　診療助教授

  • 2002年04月
    -
    2004年03月

    北里大学医学部内科学Ⅲ　助教授

全件表示 >>

このページの先頭へ▲

学歴 【 表示 ／ 非表示 】

  • 1971年04月
    -
    1977年03月

    慶應義塾大学, 医学部

    大学, 卒業

  • 1981年03月

    慶應義塾大学, 医学研究科内科学専攻, 神経内科学

    大学院, 単位取得退学, 博士

  • 1987年09月
    -
    1989年11月

    ルンド大学大学院医学研究科（スウェーデン）, 医学細胞研究科, 神経科学

    スウェーデン王国, 大学院, 修了, 博士

このページの先頭へ▲

学位 【 表示 ／ 非表示 】

  • 医学博士, 慶應義塾大学, 課程, 1984年03月

  • 医学博士, ルンド大学, 課程, 1989年11月

このページの先頭へ▲

免許・資格 【 表示 ／ 非表示 】

  • 日本国医師免許, 1977年06月

  • 神経内科専門医, 1981年07月

  • 総合内科専門医, 1984年10月

  • 脳卒中専門医, 2003年

  • 認知症専門医, 2008年10月

このページの先頭へ▲
 

研究分野 【 表示 ／ 非表示 】

  • ライフサイエンス / 神経内科学

このページの先頭へ▲

研究キーワード 【 表示 ／ 非表示 】

  • 脳循環

  • 認知症

  • 頭痛

このページの先頭へ▲

研究テーマ 【 表示 ／ 非表示 】

  • 鍼灸の作用機序に関する科学的根拠の確立と神経内科専門医と連携した鍼灸活用ガイドラインの作成 厚生労働省　平成24～26年度, 

    2012年04月
    -
    2015年03月

  • 片頭痛前兆大脳皮質拡延性抑制が神経障害性疼痛を惹起する脳可塑性と疼痛制御系の解明 文部科学省　平成22～26年度, 

    2010年04月
    -
    2015年03月

  • 血管性頭痛のレセプターメカニズムに関する研究, 

    1998年
    -
    2006年

このページの先頭へ▲
 

著書 【 表示 ／ 非表示 】

  • 神経内科Clinical Questions & Pearls 認知症

    鈴木 則宏, 中外医学社, 2016年12月

    担当範囲: 監修

  • 神経内科Clinical Questions & Pearls 脳血管障害

    鈴木 則宏, 中外医学社, 2016年10月

    担当範囲: 監修

  • 神経内科Clinical Questions & Pearls 頭痛

    鈴木 則宏, 中外医学社, 2016年05月

    担当範囲: 監修

  • 神経診察クローズアップ（改訂第2版）.　正しい病巣診断のコツ.

    鈴木 則宏, メディカルビュー社, 2015年

    担当範囲: 編集

  • 片頭痛治療薬

    鈴木 則宏, 医学書院, 2015年

    担当範囲: 87-94

全件表示 >>

このページの先頭へ▲

論文 【 表示 ／ 非表示 】

  • Trends of Antiplatelet Therapy for the Management of Moyamoya Disease in Japan: Results of a Nationwide Survey

    Oki K., Katsumata M., Izawa Y., Takahashi S., Suzuki N., Houkin K.

    Journal of Stroke and Cerebrovascular Diseases （Journal of Stroke and Cerebrovascular Diseases)  27 （ 12 ） 3605 - 3612 2018年12月

    ISSN  10523057

    　概要を見る

    © 2018 National Stroke Association Background: The efficacy and safety of antiplatelet drugs in the treatment of moyamoya disease remain unclear. This study reports results of a nationwide survey conducted in 2016 on the trends of antiplatelet therapy for moyamoya disease in Japan. Methods: Data were obtained through questionnaires related to treatment policies regarding antiplatelet drugs from each specialized stroke management department of 765 hospitals in Japan. Data were also compared between experienced facilities (defined as facilities managing more than 10 cases per year) and those less experienced (not more than 10 cases per year) to determine experts' opinion. Results: Of the 389 departments in 375 hospitals that responded, 330 departments provided medical care for moyamoya disease. Regarding ischemic stroke, numerous departments considered the use of antiplatelet drugs “in principle” (218 departments). After surgery for ischemic moyamoya disease, the use of antiplatelet drugs for a certain period of time was the most popular opinion (74 departments). Regarding asymptomatic moyamoya disease, majority departments reported no use of APDs “in principle” (256 departments). The experienced facilities reported “no use of antiplatelet drugs” more frequently than those less experienced for treating asymptomatic moyamoya disease. In moyamoya disease, aspirin was the most commonly used antiplatelet drugs followed by cilostazol and clopidogrel. Conclusions: This survey revealed details of treatment policies, and the selection of antiplatelet drugs widely varied across facilities. Further prospective studies are necessary to improve the current unclear situation regarding the use of antiplatelet drugs for the management of moyamoya disease.

  • Differences in Clinical Features in Patients with Acute Coronary Syndrome and Stroke: Japanese Multicenter Registry Results

    Naito R., Miyauchi K., Nojiri S., Suzuki N., Daida H.

    Internal medicine (Tokyo, Japan) （Internal medicine (Tokyo, Japan))  57 （ 22 ） 3233 - 3240 2018年11月

    　概要を見る

    Objective Coronary artery and cerebrovascular disease are the main causes of non-communicable diseases. In particular, acute coronary syndrome (ACS) and ischemic stroke are the most serious conditions of coronary artery disease and cerebrovascular disease, respectively. Therefore, it is important to prevent these conditions by identifying populations at high risk of these diseases. We sought to investigate the differences in the clinical features of patients with these atherothrombotic diseases in nationwide Japanese multicenter registries. Gender differences were also examined. Methods The dataset of the two nationwide multicenter registries for ACS [Prevention of AtherothrombotiC Incidents Following Ischemic Coronary (PACIFIC)] and ischemic stroke [Effective Vascular Event REduction after STroke (EVEREST)] was analyzed. Clinical features were examined and compared using datasets from the two registries. Results A total of 6,878 patients (PACIFIC: n=3,426, EVEREST: n=3,452) were evaluated. The patients' background characteristics were significantly different between the two populations. Patients with ACS tended to be younger, had a higher body mass index, had a greater prevalence of diabetes mellitus and dyslipidemia, were current smokers, and more often had a prior history of ischemia heart disease than patients with a stroke. Hypertension was more prevalent in patients with stroke than in those with ACS. The differences in patients' background characteristics between ACS and stroke in men were similar to those in the whole sample. However, the prevalence of hypertension in women was similar between the ACS and stroke groups, in contrast to the results from the whole sample. Conclusion Patients' background characteristics were significantly different between those with ACS and stroke. Gender differences were also observed.

  • Enhanced susceptibility to cortical spreading depression in two types of Na<sup>+</sup>,K<sup>+</sup>-ATPase α2 subunit-deficient mice as a model of familial hemiplegic migraine 2

    Unekawa M., Ikeda K., Tomita Y., Kawakami K., Suzuki N.

    Cephalalgia （Cephalalgia)  38 （ 9 ） 1515 - 1524 2018年08月

    ISSN  03331024

    　概要を見る

    © International Headache Society 2017. Background: Patients with familial hemiplegic migraine type 2 (FHM2) have a mutated ATP1A2 gene (encoding Na+,K+-ATPase α2 subunit) and show prolonged migraine aura. Cortical spreading depression (CSD), which involves mass depolarization of neurons and astrocytes that propagates slowly through the gray matter, is profoundly related to aura. Methods: In two types of Atp1a2-defective heterozygous mice, Atp1a2tm1Kwk (C-KO) and Atp1a2tm2Kwk (N-KO), the sensitivity and responsiveness to CSD were examined under urethane anesthesia. Results: In both cases, heterozygotes exhibited a low threshold for induction of CSD, faster propagation rate, slower recovery from DC deflection, and profound suppression of the electroencephalogram, compared to wild-type mice. A high dose of KCl elicited repeated CSDs for a longer period, with a tendency for a greater frequency of CSD occurrence in heterozygotes. The difference of every endpoint was slightly greater in N-KO than C-KO. Change of regional cerebral blood flow in response to CSD showed no significant difference. Conclusion: Heterozygotes of Atp1a2-defective mice simulating FHM2 demonstrated high susceptibility to CSD rather than cortical vasoreactivity, and these effects may differ depending upon the knockout strategy for the gene disruption. These results suggest that patients with FHM2 may exhibit high susceptibility to CSD, resulting in migraine.

  • Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial

    Misawa S., Kuwabara S., Sato Y., Yamaguchi N., Nagashima K., Katayama K., Sekiguchi Y., Iwai Y., Amino H., Suichi T., Yokota T., Nishida Y., Kanouchi T., Kohara N., Kawamoto M., Ishii J., Kuwahara M., Suzuki H., Hirata K., Kokubun N., Masuda R., Kaneko J., Yabe I., Sasaki H., Kaida K., Takazaki H., Suzuki N., Suzuki S., Nodera H., Matsui N., Tsuji S., Koike H., Yamasaki R., Kusunoki S., Misawa S., Kuwabara S., Sato Y., Yamaguchi N., Nagashima K., Katayama K., Sekiguchi Y., Iwai Y., Amino H., Suichi T., Yokota T., Nishida Y., Kanouchi T., Kohara N., Kawamoto M., Ishii J., Kuwahara M., Suzuki H., Hirata K., Kokubun N., Masuda R., Kaneko J., Yabe I., Sasaki H., Kaida K., Takazaki H., Suzuki N., Suzuki S., Nodera H., Matsui N., Tsuji S., Koike H., Yamasaki R., Kusunoki S., Nagashima T., Shimizu T., Hirotani M., Kadoya M., Nakahara J., Shimizu J., Tanaka M., Sobue G., Katsuno M., Yamaguchi H., Ogata H.

    The Lancet Neurology （The Lancet Neurology)  17 （ 6 ） 519 - 529 2018年06月

    ISSN  14744422

    　概要を見る

    © 2018 Elsevier Ltd Background: Despite the introduction of plasmapheresis and immunoglobulin therapy, many patients with Guillain-Barré syndrome still have an incomplete recovery. Evidence from pathogenesis studies suggests the involvement of complement-mediated peripheral nerve damage. We aimed to investigate the safety and efficacy of eculizumab, a humanised monoclonal antibody against the complement protein C5, in patients with severe Guillain-Barré syndrome. Methods: This study was a 24 week, multicentre, double-blind, placebo-controlled, randomised phase 2 trial done at 13 hospitals in Japan. Eligible patients with Guillain-Barré syndrome were aged 18 years or older and could not walk independently (Guillain-Barré syndrome functional grade 3–5). Patients were randomly assigned (2:1) to receive 4 weeks of intravenous immunoglobulin plus either eculizumab (900 mg) or placebo; randomisation was done via a computer-generated process and web response system with minimisation for functional grade and age. The study had a parallel non-comparative single-arm outcome measure. The primary outcomes were efficacy (the proportion of patients with restored ability to walk independently [functional grade ≤2] at week 4) in the eculizumab group and safety in the full analysis set. For the efficacy endpoint, we predefined a response rate threshold of the lower 90% CI boundary exceeding 50%. This trial is registered with ClinicalTrials.gov, number, NCT02493725. Findings: Between Aug 10, 2015, and April 21, 2016, 34 patients were assigned to receive either eculizumab (n=23) or placebo (n=11). At week 4, the proportion of the patients able to walk independently (functional grade ≤2) was 61% (90% CI 42–78; n=14) in the eculizumab group, and 45% (20–73; n=5) in the placebo group. Adverse events occurred in all 34 patients. Three patients had serious adverse events: two in the eculizumab group (anaphylaxis in one patient and intracranial haemorrhage and abscess in another patient) and one in the placebo group (depression). The possibility that anaphylaxis and intracranial abscess were related to eculizumab could not be excluded. No deaths or meningococcal infections occurred. Interpretation: The primary outcome measure did not reach the predefined response rate. However, because this is a small study without statistical comparison with the placebo group, the efficacy and safety of eculizumab could be investigated in larger, randomised controlled trials. Funding: The Japan Agency for Medical Research and Development, Ministry of Health, Labor and Welfare, and Alexion Pharmaceuticals.

  • Neuroprotective Role of Astroglia in Parkinson Disease by Reducing Oxidative Stress Through Dopamine-Induced Activation of Pentose-Phosphate Pathway

    Mashima K., Takahashi S., Minami K., Izawa Y., Abe T., Tsukada N., Hishiki T., Suematsu M., Kajimura M., Suzuki N.

    ASN Neuro （ASN Neuro)  10 2018年05月

    　概要を見る

    © The Author(s) 2018. Oxidative stress plays an important role in the onset and progression of Parkinson disease. Although released dopamine at the synaptic terminal is mostly reabsorbed by dopaminergic neurons, some dopamine is presumably taken up by astroglia. This study examined the dopamine-induced astroglial protective function through the activation of the pentose-phosphate pathway (PPP) to reduce reactive oxygen species (ROS). In vitro experiments were performed using striatal neurons and cortical or striatal astroglia prepared from Sprague-Dawley rats or C57BL/6 mice. The rates of glucose phosphorylation in astroglia were evaluated using the [ 14 C]deoxyglucose method. PPP activity was measured using [1- 14 C]glucose and [6- 14 C]glucose after acute (60 min) or chronic (15 hr) exposure to dopamine. ROS production was measured using 2′,7′-dichlorodihydrofluorescein diacetate. The involvement of the Kelch-like ECH-associated protein 1 (Keap1) or nuclear factor-erythroid-2-related factor 2 (Nrf2) system was evaluated using Nrf2 gene knockout mice, immunohistochemistry, and quantitative reverse transcription polymerase chain reaction analysis for heme oxygenase-1. Acute exposure to dopamine elicited increases in astroglial glucose consumption with lactate release. PPP activity in astroglia was robustly enhanced independently of Na + -dependent monoamine transporters. In contrast, chronic exposure to dopamine induced moderate increases in PPP activity via the Keap1/Nrf2 system. ROS production from dopamine increased gradually over 12 hr. Dopamine induced neuronal cell damage that was prevented by coculturing with astroglia but not with Nrf2-deficient astroglia. Dopamine-enhanced astroglial PPP activity in both acute and chronic manners may possibly reduce neuronal oxidative stress.

全件表示 >>

このページの先頭へ▲

KOARA（リポジトリ）収録論文等 【 表示 ／ 非表示 】

全件表示 >>

このページの先頭へ▲

研究発表 【 表示 ／ 非表示 】

  • Induction of inducible nitric oxide synthase affects the function of blood-brain barrier in the rat

    Suzuki N, Fukuuchi Y, Koto A, Morita Y, Shimizu T, Takao M, Aoyama M

    Keio International Symposium for Life Sciences and Medicine Ischemic Blood Flow in the Brain (6th ; 1999), 

    1999年11月

  • 脳血管におけるcalbindin─D28k陽性神経線維の分布について

    鈴木則宏，厚東篤生，森田陽子，後藤淳，清水利彦，高尾昌樹，大友哲，福内靖男

    第11回日本脳循環代謝学会, 

    1999年10月

  • Occurrence and distribution of calbindin-D28K in rat cerebrovansculature

    Shimizu T, Fukuuchi Y, Koto A, Suzuki N, Morita Y, Gotoh J, Takao M, Otomo S

    International Symposium on Cerebral Blood Flow, Metabolism and Function (19th ; 1999), 

    1999年06月

  • Neurokinin-1 receptors in parasympathetic nerves in cerebral blood vessels

    Suzuki N, Koto A, Morita Y, Shimizu T, Takao M, Otomo S, Sakai F, Fukuuchi Y

    International Symposium on Cerebral Blood Flow, Metabolism and Function (19th ; 1999), 

    1999年06月

  • Effects of cytochrome P450 inhibitors on cerebral blood flow in the rat

    Morita Y, Fukuuchi Y, Koto A, Suzuki N, Shimizu T, Takao M, Otomo S

    International Symposium on Cerebral Blood Flow, Metabolism and Function (19th ; 1999), 

    1999年06月

全件表示 >>

このページの先頭へ▲

Works 【 表示 ／ 非表示 】

  • 学務委員会委員

    2003年10月
    -
    2005年09月
    , 

    その他

このページの先頭へ▲

受賞 【 表示 ／ 非表示 】

  • 平成12年度　第33回　財団法人三井厚生事業団医学研究助成

    2000年, 財団法人三井厚生事業団

  • 平成22年度　日本医師会医学研究奨励賞

    2010年, 日本医師会

  • 平成22年度　Award of Neuroscience Research Top Cited Article 2008-2010

    2011年, エルゼビア出版株式会社

  • 美原賞

    鈴木則宏, 2015年02月, 公益信託美原脳血管障害研究振興基金, 神経血管単位（Neurovascular unit）に着目した脳虚血の病態改善および機能回復へ向けた包括的研究

  • 慶應義塾賞

    2017年10月, 慶應義塾大学

    受賞区分： 塾内表彰等

このページの先頭へ▲
 

担当授業科目 【 表示 ／ 非表示 】

  • 内科学

    2019年度

  • 内科学講義

    2019年度

このページの先頭へ▲

担当経験のある授業科目 【 表示 ／ 非表示 】

  • 内科学「神経」

    慶應義塾

    2015年04月
    -
    2016年03月
    , 

    通年, 講義

このページの先頭へ▲
 

所属学協会 【 表示 ／ 非表示 】

  • 日本内科学会, 

    1977年05月
    -
    継続中

  • 日本神経学会, 

    1977年05月
    -
    継続中

  • 日本脳卒中学会, 

    1977年05月
    -
    継続中

  • 日本頭痛学会, 

    1997年
    -
    継続中

  • 日本認知症学会, 

    2004年
    -
    継続中

全件表示 >>

このページの先頭へ▲

委員歴 【 表示 ／ 非表示 】

  • 2008年
    -
    2012年

    理事長, 日本脳循環代謝学会

  • 2010年
    -
    2012年

    理事, 日本内科学会

  • 2012年
    -
    継続中

    資格認定試験委員会委員長, 日本内科学会

  • 2013年
    -
    継続中

    編集委員長, 日本神経学会

  • 2014年
    -
    2016年

    理事, 日本内科学会

全件表示 >>

このページの先頭へ▲